Jiya in an amended S-1 said it may issue a maximum of 11.5 million shares, which would generate up to $115 million in the offering. The SPAC is focused on biopharmaceutical companies. Read more.
Jiya Amends $100M IPO Prospectus
Related Posts
FinServ/Katapult Definitive Proxy Now Effective
Total consideration paid to Katapult’s existing shareholders would be $833 million.
Blue Safari Group Prices $50M IPO
Blue Safari Group is targeting companies that are in the FinTech, InfoTech, InsurTech and business services.
$200M IPO Filed by Glass Houses Acquisition
The SPAC in the S-1 filing said it intends "to search for a target business that provides critical resources and/or services to the technologies powering the 21st century industrial economy."
DP Cap Acquisition Sweetens Offer on Extension Proposal
DP Cap raised $200 million in a December 2021 IPO, although redemptions since them have eaten away at the SPAC’s cash in trust, which was down to about $44 million as of Dec. 31.